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318 AnnStudy objective: We seek to examine the efﬁcacy and safety of prereperfusion emergency medical services (EMS)–
administered intravenous metoprolol in anterior ST-segment elevation myocardial infarction patients undergoing
eventual primary angioplasty.
Methods: This is a prespeciﬁed subgroup analysis of the Effect ofMetoprolol in CardioprotectionDuring an AcuteMyocardial
Infarction trial population, who all eventually received oral metoprolol within 12 to 24 hours. We studied patients receiving
intravenous metoprolol by EMS and compared them with others treated by EMS but not receiving intravenous metoprolol.
Outcomes included infarct size and left ventricular ejection fraction on cardiac magnetic resonance imaging at 1 week, and
safety by measuring the incidence of the predeﬁned combined endpoint (composite of death, malignant ventricular
arrhythmias, advanced atrioventricular block, cardiogenic shock, or reinfarction) within the ﬁrst 24 hours.
Results: From the total population of the trial (N¼270), 147 patients (54%) were recruited during out-of-hospital
assistance and transferred to the primary angioplasty center (74 intravenous metoprolol and 73 controls). Infarct size
was smaller in patients receiving intravenous metoprolol compared with controls (23.4 [SD 15.0] versus 34.0 [SD 23.7] g;
adjusted difference –11.4; 95% conﬁdence interval [CI] –18.6 to –4.3). Left ventricular ejection fraction was higher in
the intravenous metoprolol group (48.1% [SD 8.4%] versus 43.1% [SD 10.2%]; adjusted difference 5.0; 95% CI 1.6 to
8.4). Metoprolol administration did not increase the incidence of the prespeciﬁed safety combined endpoint: 6.8%
versus 17.8% in controls (risk difference –11.1; 95% CI –21.5 to –0.6).
Conclusion: Out-of-hospital administration of intravenous metoprolol by EMS within 4.5 hours of symptom onset in our
subjects reduced infarct size and improved left ventricular ejection fraction with no excess of adverse events during the
ﬁrst 24 hours. [Ann Emerg Med. 2015;65:318-324.]
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Background
Long-term oral b-blocker therapy improves survival after acute
myocardial infarction.1,2 Current ST-segment elevation myocardial
infarction (STEMI) guidelines recommend the initiation of oral
b-blocking agents in the ﬁrst 24 hours after myocardial infarction
in all patients without contraindications.3,4 However, whether
intravenous b-blocker administration early during ongoing
myocardial infarction has any incremental value is less clear.5 Data
on the beneﬁts of early intravenous b-blocker initiation iners are listed in the Appendix.
als of Emergency Medicinemyocardial infarction are mainly from the prereperfusion era, with
limited information for patients undergoing primary angioplasty6,7
or for animal models.8,9 Classic clinical trials on the effect of early
intravenous b-blockade during ongoing myocardial infarction
recruited patients in the hospital environment; it is unknown
whether earlier initiation of intravenous b-blockade in the out-of-
hospital setting is safe or whether it has any clinical beneﬁt.
A recently published multicenter randomized clinical trial (Effect
of Metoprolol in Cardioprotection During an Acute Myocardial
Infarction [METOCARD-CNIC]) examined the beneﬁts of very
early intravenous metoprolol initiation in STEMI patients
undergoing primary percutaneous coronary intervention.10 ThemainVolume 65, no. 3 : March 2015
Mateos et al Out-of-Hospital Intravenous Metoprolol for STEMIEditor’s Capsule Summary
What is already known on this topic
Early therapy in acute ST-segment elevation
myocardial infarction improves outcomes, and out-
of-hospital care providers have a unique early
opportunity to intervene.
What question this study addressed
Is out-of-hospital intravenous metoprolol delivered
by ambulances staffed with physicians and nurses safe
and beneﬁcial for patients with acute anterior ST-
segment elevation myocardial infarction?
What this study adds to our knowledge
One hundred forty-seven subjects drawn from a
larger Spanish trial were randomized to metoprolol or
placebo. On average, patients receiving metoprolol
had smaller infarct size and higher ejection fractions
at 1 week, without an increase in adverse events
during the ﬁrst 24 hours.
How this is relevant to clinical practice
Intravenous metoprolol in the ﬁeld when
administered by physicians is safe and alters early
outcomes after acute myocardial infarction. Any
longer-term beneﬁt or harm is unknown, and
emergency medical services delivery was not
compared with emergency department delivery,
limiting widespread use.outcome was a smaller infarct size (mean 20%) in patients treated
with pre–percutaneous coronary intervention intravenous
metoprolol absent any safety signals. This beneﬁt was maintained
with higher left ventricular ejection fraction at 6 months, lower
incidence of severe left ventricular ejection fraction depression,
and fewer readmissions because of heart failure.11
The main objective of this prespeciﬁed12 subanalysis is to examine
the efﬁcacy (infarct size and left ventricular ejection fraction, the2main
predictors of long-termmortality after STEMI13) and safety (incidence
of the prespeciﬁed safety major cardiac adverse events at 24 hours) of
early intravenous metoprolol in anterior STEMI. We hypothesized
that intravenous metoprolol administration by emergency medical
services (EMS) providers en route to the percutaneous coronary
intervention center is efﬁcacious and safe for patients with
suspected anterior STEMI of Killip class less than or equal to II.12
MATERIALS AND METHODS
Study Design
The METOCARD-CNIC was a multicenter, randomized,
parallel-group, single-blinded trial carried out in 7 hospitals
(in 4 regions across Spain) between 2010 and 2012.12Volume 65, no. 3 : March 2015Selection of Participants
Patients eligible were aged 18 to 80 years and with symptoms
of ischemic chest pain of less than or equal to 4.5 hours’ duration
(to ensure anticipated reperfusion by primary percutaneous
coronary intervention within 6 hours from symptom onset) and
ST-segment elevation greater than or equal to 0.2 mV in 2 or
more contiguous precordial leads (V1 to V5). Exclusion criteria
included Killip class III or IV at presentation (acute pulmonary
edema or cardiogenic shock), complete left bundle branch block,
PR interval greater than 240 ms or type II or III atrioventricular
block, pulse rate persistently less than 60 beats/min or systolic
blood pressure less than 120 mm Hg, long-term ongoing
treatment with b-blocker agents, active bronchodilator
treatment, and history of myocardial infarction. The ethics
committees and institutional review boards at each participating
center approved the design, and all subjects gave written
informed consent before inclusion.
Interventions
We randomized the parent trial subjects at the EMS:
SUMMA112 (Servicio de Urgencias Médicas de Madrid), 061
Galicia, SAMUR-PC (Servicio de Asistencia Municipal de
Urgencia y Rescate-Protección Civil), or at the percutaneous
coronary intervention center. This article applies only to the
population recruited at the out-of-hospital EMS setting. The
randomization center was run continuously by a group of trained
nurses and a supervising physician. All ambulances in the
participating EMS have 1 physician, 1 nurse, and 1 emergency
medical technician on board. We performed permuted block
randomization, stratifying subjects by 4 variables that have a
potential inﬂuence on infarct size: time from symptom onset
(1.5 hours; >1.5 hours), sex, diabetes status, and age (<60
years; 60 years).
For patients allocated to active treatment, metoprolol tartrate
was administered intravenously as previously described (up to
3 boluses of 5 mg 2 minutes apart),13 with reassessment of pulse
rate, PR interval, blood pressure, and lung auscultation after each
bolus. Further bolus administration was interrupted if systolic blood
pressure decreased to less than 100 mmHg, pulse rate decreased to
less than 60 beats/min, or the patient developed any degree of
atrioventricular block or rales in the mid-upper lung ﬁelds.
Control subjects did not receive any intravenous metoprolol
before reperfusion, either from EMS or in the emergency
department (ED). All patients received aspirin and an approved
P2Y12 inhibitor as early as possible after the ﬁrst medical contact
in the EMS setting per protocol. The rest of the pharmacologic
treatment was established by local physicians following clinical
guideline recommendations.3,4 Decisions about access site,
performance of thrombus aspiration, and stent type were left
to physician preference. All patients, including those randomized
to control, received long-term oral b-blocker therapy within
24 hours after infarction.3,4
We performed cardiac magnetic resonance imaging studies 1
week after STEMI for all patients fulﬁlling inclusion criteria with
enzymatically conﬁrmed STEMI. The interpreters were expertAnnals of Emergency Medicine 319
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laboratory in CNIC (Madrid) and using dedicated software
(Qmass MR 7.5; Medis, Leiden, the Netherlands). Each
quantiﬁed myocardial necrosis (grams and percentage of left
ventricular mass) on late gadolinium enhancement sequences by
drawing of the enhanced area using half full-width method.
Next, we calculated left ventricular ejection fraction by Simpson’s
method after tracing of the endocardial and epicardial contours in
end-systolic and end-diastolic short-axis slices.12Outcome Measures
The primary prespeciﬁed efﬁcacy outcome was infarct size as
quantiﬁedbycardiacmagnetic resonance 1weekpostinfarction.The
secondary efﬁcacy outcome measure was left ventricular ejection
fraction on 1-week cardiacmagnetic resonance. Primary prespeciﬁed
major cardiac adverse events safety endpoint was predeﬁned as a
composite of all-cause mortality, malignant ventricular arrhythmias,
advanced atrioventricular block, cardiogenic shock, and reinfarction
during the ﬁrst 24 hours after STEMI. A clinical events committee
adjudicated any data concerns and was blinded to the study
treatment after reviewing the original source of data.Primary Data Analysis
Qualitative variables are expressed as percentages and
continuous variables as mean (SD) or median (25th to 75th
percentile), according to data distribution evaluated with graphic
methods. We compared normally distributed variables by
parametric methods, non-normal data by nonparametric
methods (Wilcoxon rank-sum test), and categorical data by exact
methods. All hypotheses were tested to a 2-sided .05 level of
signiﬁcance. We used an intent-to-treat principle for efﬁcacy and
per-treatment approach for safety analyses, and missing values
were not replaced. The cardiac magnetic resonance data (infarct
size and left ventricular ejection fraction) analyses used linear
regression models, with treatment effect estimates (and 95%
conﬁdence intervals [CIs]) presented both without and with
adjustment (for the 4 stratiﬁcation variables). Finally, we
examined heterogeneity of treatment effects among prespeciﬁed
subgroups, using regression models or the Mantel-Haenszel
method. Data were analyzed with IBM SPSS Statistics for
Windows, version 20.0 (IBM Corporation, Armonk, NY).RESULTS
Characteristics of Study Subjects
Between November 2010 and October 2012, a total of 147
patients of the 270 parent trial cohort (54%) were recruited in
the out-of-hospital setting and constitute the current study
population.
From the 147 patients recruited in the out-of-hospital setting, 74
were randomized to intravenous metoprolol: 48 of 74 patients
(65%) received 3 metoprolol boluses (15 mg), 12 of 74 patients
(16%) received a total of 2metoprolol boluses (10mg), and 13 of 74
patients (17%) received only 1 metoprolol bolus (5 mg). Finally, 1320 Annals of Emergency Medicinepatient randomized to intravenous metoprolol did not receive
any metoprolol bolus because of a vagal reaction. A ﬂow chart of
enrollment of the patients in the study is shown in the Figure.
One patient in the intravenous metoprolol group withdrew
consent. Sixteen patients (11 in the intravenous metoprolol
group and 5 controls) were not scheduled for cardiac magnetic
resonance because of either erroneous recruitment or no evidence
of infarction (no cardiac damage measured by biomarker
elevation). Eleven patients initially scheduled for the imaging test
did not ﬁnally undergo cardiac magnetic resonance because of
claustrophobia (n¼4), poor clinical status (n¼6, 3 patients in
each group), or technical problems (n¼1). Hence, 119 patients
were ﬁnally included in the statistical analysis for efﬁcacy
outcomes (infarct size and left ventricular ejection fraction on
cardiac magnetic resonance), and safety analysis was carried out
in the total study population (n¼147).
Baseline clinical characteristics and hemodynamic situation
are summarized in Table 1. No differences were found between
treatment groups in terms of demographic data, cardiovascular
risk factors, hemodynamic status, or pre–percutaneous coronary
intervention thrombolysis in myocardial infarction ﬂow. We
found a trend for longer pain-to-balloon time (ischemia
duration) in the prereperfusion metoprolol group (207.9 [SD
65.5] versus 193.7 [SD 64.8] minutes in the control): time from
chest pain onset to randomization was 110.1 minutes (SD 65.5)
in the intravenous metoprolol group and 104.2 minutes (SD
58.3) in the control. Time from randomization to reperfusion
was 97.8 minutes (SD 35.9) in the intravenous metoprolol group
and 89.5 minutes (SD 31.2) in the control.
Infarct size calculated either in grams of infarcted tissue (23.4 [SD
15.0] versus 34.0 [SD 23.7]; adjusted treatment effect –11.4; 95%
CI –18.6 to –4.3) or as a percentage of the total left ventricular mass
(18.9% [SD 11.3%] versus 24.5% [SD 14.4%]; adjusted treatment
effect –5.85; 95% CI –10.6 to –1.1) was signiﬁcantly reduced by
prereperfusion intravenous metoprolol (Table 2).
Left ventricular ejection fraction was higher in the intravenous
metoprolol group (48.1% [SD 8.4%] versus 43.1% [SD 10.2%];
adjusted treatment effect 5.0; 95% CI 1.6 to 8.4), mainly driven
by a decrease in left ventricular end-systolic volume (87.0 mL
[SD 27.5] versus 100.3 mL [SD 36.1]; adjusted treatment effect
–15.2; 95% CI –26.2 to –4.3).
Intravenous metoprolol administration in the acute phase of
STEMI during EMS assistance and transfer to a percutaneous
coronary intervention center did not increase the incidence of
major adverse cardiac events in the ﬁrst 24 hours after myocardial
infarction: 6.8% of patients in the intravenous metoprolol group
compared with 17.8% of controls (risk difference –11.1; 95% CI
–21.5 to –0.6). The individual components of major cardiac
adverse events are detailed in Table 3. There were no cases of
sinus bradycardia requiring intervention (drugs or pacing), and
there were 4 cases of sinus bradycardia not requiring intervention
(1 intravenous metoprolol and 3 controls).
The examination of both prespeciﬁed subgroups showed no
heterogeneity in the effects of treatment for either efﬁcacy or the
safety endpoint (Tables 2 and 3).Volume 65, no. 3 : March 2015
Figure. Flow chart of enrollment of the patients in the study. Erroneous recruitment were previous treatment with b-blockers (3 i.v.
metoprolol and 2 controls), and no ECG criteria (5 i.v. metoprolol and 1 control). There were 5 patients with no enzymatic evidence
of infarction (3 i.v. metoprolol and 2 controls). CMR, Cardiac magnetic resonance.
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Our observations are based on a relatively small sample size.
The lack of placebo arm may have inﬂuenced the effect of
treatment allocation on pain-to-balloon time (ischemia duration).
We also did not study ED intravenous therapy. This trial included
patients with anterior STEMI, and thus the effect of intravenous
metoprolol in the acute setting has not been tested in other
scenarios with a higher risk of advanced atrioventricular block,
such as inferior myocardial infarction. The METOCARD-CNIC
used the intravenous b1 selective blocker metoprolol. Given that
not all b-blockers, not even b1-selective ones, share the same
pharmacologic properties, it cannot be assumed that these beneﬁts
apply to all b-blockers. Evidence reported here relates to injectable
metoprolol tartrate. Finally, the representation of women in our
trial (13%) is lower than that in actual practice. In this regard,
the percentage of women in our trial is lower than that of
contemporaneous STEMI trials (in which 20% to 25% of cases
are women) for uncertain reasons and effect.
DISCUSSION
Ourdata show that the intravenous administration ofmetoprolol
during EMS assistance and transfer to the primary percutaneous
coronary intervention center is safe and results in a reduction of
infarct size, as well as an increase in left ventricular ejection fraction
compared with that in patients not receiving pre–percutaneous
coronary intervention metoprolol. Infarct size and left ventricularVolume 65, no. 3 : March 2015ejection fraction are the 2 main predictors of long-term morbidity
and mortality in STEMI survivors.14 Intravenous metoprolol
administration in the out-of-hospital setting did not increase the
incidence of the prespeciﬁed safety composite endpoint.
The role of out-of-hospital EMS is crucial in the ﬁrst hours
of ongoing STEMI: early triage and diagnosis, rapid activation
of the catheterization laboratory, and initial therapeutic
management.15-16 Several studies have shown the efﬁcacy of
EMS-based approaches for early ECG diagnosis of STEMI and
rapid transfer to a percutaneous coronary intervention–capable
center to reduce total ischemic time.17-20 The improvement of
extrahospital management has resulted in a signiﬁcant reduction
of the pain-to-balloon duration; however, despite this reduction
in the total duration of ischemia, mortality in the percutaneous
coronary intervention era has remained unchanged.21 Therefore,
there is a clear need for additional actions to reduce mortality in
STEMI patients treated by percutaneous coronary intervention.
Early intravenous b-blocker administration during the acute
stages of STEMI is not routine practice in EMS care. The very
early intravenous b-blockade was hampered mainly because of
the results of the Clopidogrel and Metoprolol in Myocardial
Infarction Trial (COMMIT) trial.5 This study randomized more
than 45,000 STEMI patients to either early metoprolol followed
by oral administration thereafter or placebo. Early metoprolol
treatment reduced reinfarction and ventricular ﬁbrillation rates,
but this effect was counterbalanced by an increase in cardiogenicAnnals of Emergency Medicine 321
Table 1. Baseline characteristics of the study population.
Baseline Characteristics
All Patients (n[147)
Intravenous
Metoprolol
(n[74)
Control
(n[73)
Age, y* 59 (12) 59 (10)
Female sex, No. (%) 12 (16.2) 13 (17.8)
BMI, kg/m2* 27.6 (3.7) 27.7 (4.2)
Hypertension, No. (%) 27 (39.1) 30 (41.7)
Diabetes mellitus, No. (%) 12 (16.9) 13 (17.8)
Dyslipidemia, No. (%) 30 (44.1) 27 (38)
Smoking, No. (%) 37 (53.6) 34 (47.2)
Pain-to-balloon time, min* 208 (66) 194 (65)
Killip class at recruitment, No. (%)
I 67 (90.5) 60 (82.2)
II 7 (9.5) 13 (17.8)
Pre-PCI TIMI ﬂow 0–1 (occluded artery),
No. (%)
51 (76.1) 53 (74.6)
SBP at inclusion, mm Hg* 143 (20) 142 (20)
DBP at inclusion, mm Hg* 92 (15) 90 (14)
HR at inclusion, bpm* 81 (11) 81 (14)
SBP after intravenous metoprolol, mm Hg*† 129 (20) —
DBP after intravenous metoprolol, mm Hg*† 85 (17) —
HR after intravenous metoprolol, mm Hg*† 68 (9) —
Adjunctive out-of-hospital treatment
Aspirin, No. (%) 65 (100) 69 (100)
Thienopyridine, No. (%) 64 (98.5) 67 (97.1)
—, Not applicable; BMI, body mass index; PCI, percutaneous coronary intervention;
TIMI, thrombolysis in myocardial infarction; SBP, systolic blood pressure; DBP,
diastolic blood pressure; HR, pulse rate.
The missing data were not imputed. Missing values were 6 for hypertension status,
8 for dyslipidemia, 6 for smoking, 9 for pre-PCI TIMI-ﬂow, 13 for aspirin administration
in the out-of-hospital setting, and 13 for thienopyridine administration in the out-of-
hospital setting.
*Data are expressed as mean (SD).
†Measurements after the ﬁnal dose of metoprolol.
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mortality. The potentially life-threatening adverse effects of very
early intravenous metoprolol shown in COMMIT and the lack
of clear beneﬁt of this strategy do not encourage the introduction
of this therapy in the out-of-hospital environment. However,
the clinical scenario of the COMMIT trial is different from the
scenario of most of the STEMI patients treated according to
clinical guidelines: (1) reperfusion by primary percutaneous
coronary intervention was an exclusion criterion in COMMIT;
(2) patients enrolled in COMMIT presented very late (mean
symptoms onset to lytic therapy was >10 hours); and (3) KillipTable 2. Cardiac magnetic resonance–derived results (efﬁcacy data).
Cardiac Magnetic
Resonance Imaging
Parameters
Intravenous
Metoprolol (n[57),
Mean (SD)
Control (n[62),
Mean (SD)
LVEF, % 48.1 (8.4) 43.1 (10.2)
LVEDV, mL 165.5 (36.9) 172.8 (42.7)
LVESV, mL 87.0 (27.5) 100.3 (36.1) 
Infarct size, % LV 18.9 (11.3) 24.5 (14.4)
Infarct size, g 23.4 (15) 34.0 (23.7) 
LVEF, Left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV
322 Annals of Emergency Medicineclass III (a recognized contraindication for intravenous b-blocker
therapy) was not an exclusion criterion in COMMIT. In fact, the
excess of mortality was especially apparent in the subgroup of
patients presenting with a Killip class III STEMI. Contrary to
COMMIT, the METOCARD-CNIC trial recruited patients
presenting early after symptom onset (6 hours) and undergoing
primary percutaneous coronary intervention, and excluded
patients with Killip class III to IV. The subgroup analysis
presented in this work demonstrates that an adequate patient
selection results in a clear clinical beneﬁt (smaller infarctions and
higher left ventricular ejection fraction), with no associated harm.
The environment of the METOCARD-CNIC deserves to be
mentioned. In Spain, most of the ambulances attending STEMI
are physician manned, which could affect the selection and care
of patients in our trial. However, our clinical criteria may be used
by any EMS team composition. ECG interpretation may differ
between physician- and nonphysician-staffed ambulances, but
telemetric ECG transmissions to a command center might
mitigate this concern.22
The infarct size reduction and left ventricular ejection fraction
increase observed in the subgroup of patients recruited in the
out-of-hospital setting and treated by metoprolol is larger than
that reported in the entire cohort of the METOCARD-CNIC.10
Similarly, the reduction of the composite major cardiac adverse
events at 24 hours is greater than that documented in the entire
cohort of patients. This apparent tendency for a greater beneﬁt
observed in patients receiving intravenous metoprolol during
out-of-hospital care suggests that the earlier the metoprolol
treatment during a STEMI, the greater the clinical beneﬁts.
Our results show a nonsigniﬁcant increase in pain-to-balloon
time (ischemia duration) in the intravenous metoprolol group.
This ﬁnding might be a result of metoprolol boluses preparation
and hemodynamic reassessment after each metoprolol dose
(metoprolol was injected in up to three 5-mg boluses, 2 minutes
apart). Before each bolus, blood pressure, pulse rate, PR interval,
and lung auscultation were required per protocol.12 Perhaps
implementation of this intervention led to delayed patient
transport to the catheterization laboratory, resulting in slight
prolonged ischemic times (one of the most important
determinants of ﬁnal scar size). In our study, out-of-hospital
patients treated with intravenous metoprolol during transfer to
the percutaneous coronary intervention center, despite showing a
modest nonsigniﬁcant prolongation of pain-to-balloon time,
showed a 30% reduction in ﬁnal infarct size, along with aDifference (95% CI)
Unadjusted
Difference (95% CI)
Adjusted for Stratiﬁcation
Variables
Interaction
P Value
5.0 (1.6 to 8.5) 5.0 (1.6 to 8.4) .06
7.3 (21.9 to 7.4) 11.1 (23.9 to 1.8) .44
13.2 (25.1 to 1.5) 15.2 (26.2 to 4.3) .15
5.6 (10.4 to 0.8) 5.85 (10.6 to 1.1) .15
10.6 (18.0 to 3.2) 11.4 (18.6 to 4.3) .09
, left ventricular end-systolic volume.
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Table 3. Adverse cardiac events during the ﬁrst 24 hours after STEMI.
Adverse Cardiac Events
during the First 24 Hours
All Patients (n[147)
Risk Difference
(95% CI)
Interaction
P Value
Intravenous
Metoprolol (n[74),
No. (%)
Control (n[73),
No. (%)
MACE 5 (6.8) 13 (17.8) 11.1 (21.5 to 0.6) .31
All-cause mortality 0 1 (1.4) 1.4 (0.4 to 1.3) —
Malignant ventricular arrhythmia 3 (4.1) 7 (9.6) 5.5 (13.6 to 2.6) .76
Advanced AV block 1 (1.4) 1 (1.4) 0 (3.8 to 3.7) —
Cardiogenic shock 2 (2.7) 6 (8.2) 5.5 (12.8 to 1.8) .24
Reinfarction 0 0 — —
MACE, Major adverse cardiac events (composite of death, malignant ventricular arrhythmias, ie, ventricular ﬁbrillation or sustained ventricular tachycardia), advanced AV block,
cardiogenic shock, and reinfarction; AV, atrioventricular.
Mateos et al Out-of-Hospital Intravenous Metoprolol for STEMIsigniﬁcant increase in left ventricular ejection fraction, suggesting
that the cardioprotective effects of metoprolol outweigh the
longer pain-to-balloon time derived from its administration. In
addition, this strategy reduces the incidence of adverse effects
during the transfer of patients to the percutaneous coronary
intervention center, something that, apart from the evident
clinical beneﬁt, would be welcome by professionals caring for
patients in the out-of-hospital setting.
In summary, EMS intravenous metoprolol administration in
the acute setting of myocardial infarction is safe and efﬁcacious
during transfer to percutaneous coronary intervention facilities in
selected patients (4.5 hours Killip class I or II anterior STEMI
patients without baseline ECG conduction abnormalities).
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